Navigation Links
Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis
Date:9/21/2009

SEATTLE, Sept. 21 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced today that it will re-focus its resources on the approval of OPAXIO(TM) for its potential superiority indication in maintenance therapy for ovarian cancer. The Gynecologic Oncology Group (GOG) is conducting an ongoing phase III trial that evaluates the use of 12 months of OPAXIO therapy versus an untreated control arm. To date, 600 patients have been enrolled in this trial. CTI has discussed with the GOG, several strategies for conducting an interim analysis which could potentially result in an earlier registration. In addition, given the encouraging results of treatment of advanced esophageal cancer with OPAXIO to be reported at the upcoming International Society of Gastrointestinal Oncology Annual Meeting, CTI plans on meeting with the Food and Drug Administration (FDA) to discuss an additional registration study utilizing OPAXIO as a radiation sensitizer in the treatment of advanced esophageal cancer.

CTI has notified the European Medicines Agency (EMEA) of its decision to withdraw its Marketing Authorization Application (MAA) for a non-inferiority indication in non-small cell lung cancer (NSCLC).

"Given that we have reached a milestone in the ovarian cancer trial enrollment coupled with the reservations the Committee for Medicinal Products for Human Use (CHMP) expressed about the control arm activity in the NSCL cancer study we believe it makes best sense for CTI to focus its efforts with OPAXIO on superiority applications like the first-line ovarian cancer trial as well as the exciting new potential application as a radiation sensitizer," noted Craig W. Philips, President of CTI. "Both of these studies would be landmark trials and first in class for this novel bioengineered taxane. We look forward to continuing to work with the GOG and ultimately the FDA on a registr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... KONG , August 28, 2015 ... in collaboration with one of the leading academics in ... (current world record holder in life extension for model ... insights into biology of aging and age-related diseases, primarily, around ... The work has just been published as "Stability analysis of ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
(Date:8/28/2015)... 28, 2015 , Joint research by ... from Biostar , Published in ,Stem Cells Translational ... lifespan through multiple IV administration of Adipose-derived MSC ... expectancy found , Commercialization within 5 years expected ... possibility that adult mesenchymal stem cells (MSCs) may extend ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... 12 Novartis Pharma AG has entered into an agreement ... (iloperidone), a new oral medication that is approved by the ... of adults with schizophrenia. Novartis plans to launch Fanapt ... part of the agreement with Vanda Pharmaceuticals Inc., Novartis will ...
... Conn., Oct. 12 VION PHARMACEUTICALS, INC. (OTC ... investment banking firm Merriman Curhan Ford & Co. to assist ... of a restructuring of the Company and its debt and ... may also consider financing options. , As previously reported, the ...
Cached Medicine Technology:Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 2Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 3Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 4Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 5Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 6Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 7Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia 8Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives 2Vion Pharmaceuticals Engages Merriman Curhan Ford to Evaluate Strategic Alternatives 3
(Date:8/28/2015)... Columbus, Ohio (PRWEB) , ... August 28, 2015 ... ... Saturday’s Imagine No Malaria Day at the Zoo to celebrate children helping children, ... people and their congregations throughout West Ohio have contributed to the United Methodist ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Medical Devices:, Understanding the FDA’s Position and Best Practices for Compliance, **Presented ... , This workshop, chaired by internationally renowned expert Fubin Wu, has ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... of high grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine ... a finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... of the Veterans Award, honoring military veterans leading in business. Mr. Troy ... , The inaugural Nashville Business Journal's 2015 Veterans Awards will recognize ...
(Date:8/28/2015)... ... , ... Northridge dentists Dr. Elyson and Dr. Assili are now ... currently receive a one hour treatment of this teeth whitening option. Zoom whitening ... of unique features that can turn teeth up to nine shades whiter. Effective on ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2
... 45%, ATLANTA, Dec. 5 Mary Washington ... Patient Flow initiative to,dramatically improve performance. Results include ... reduction in radiology turnaround time for key emergency,procedures, ... teams working on specific parts of the ED ...
... Care for Millions of Americans, WASHINGTON, Dec. 5 ... access to medical treatment, HHS,Secretary Mike Leavitt said today ... or expand 1,200 community health centers., Health centers ... ability to pay. Charges for health care services at,health ...
... Sage Software Healthcare, Inc.,announced today that more ... Sage Practice Management system during the 2007 fiscal ... the Intergy EHR by,Sage Electronic Health Records system., ... grow, within our,customer base as well as new ...
... Navitas Cancer Rehabilitation Centers of,America, Inc. ... and,comprehensive cancer rehabilitation services, is pleased to ... located on the campus of Presbyterian/St.,Luke,s Medical ... services,agreement with Presbyterian/St. Luke,s to provide its ...
... also hit new high last year , , WEDNESDAY, Dec. 5 ... the number of teenagers having babies in the United States ... Wednesday. , That startling news was accompanied by additional data ... for unmarried women having babies as well as for Caesarean ...
... In about 20 percent of women with breast ... resonance imaging reveals important diagnostic information that alters their ... 5). , This study was presented at the 119th ... 2-5 in Hot Springs, Va., and will appear in ...
Cached Medicine News:Health News:SciHealth Inc. Helps Mary Washington Hospital Improve Emergency Department Performance 2Health News:HHS Marks Expansion of 1200th Health Center, Meeting Key Bush Goal 2Health News:Sage Software Healthcare, Inc. Announces Intergy by Sage and Intergy EHR by Sage installations for 2007 2Health News:Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian / St. Luke's Medical Center 2Health News:Navitas Opens Cancer Rehabilitation Center in Denver in Conjunction With Presbyterian / St. Luke's Medical Center 3Health News:Teen Birth Rates Up for First Time in 14 Years, U.S. Reports 2Health News:Teen Birth Rates Up for First Time in 14 Years, U.S. Reports 3Health News:Breast MRI spots other cancers, may alter treatment plan 2Health News:Breast MRI spots other cancers, may alter treatment plan 3Health News:Breast MRI spots other cancers, may alter treatment plan 4
... new Eclipse TS-100 is an innovative ... high quality tool complements any research ... CFI60 optics offer brilliant, sharp ... superb optical performance with high resolution ...
... Nikon Instruments Inc., a world leader ... the introduction of its new Universal ... Nikon Eclipse upright microscope models, including ... This Universal Epi Illuminator provides ...
... monochrome digital CCD camera ideal for demanding low-light ... high-resolution images with outstanding clarity and detail. ... Live Image Frame Rate - ... 170x120 (8x8) Image Display Speed ...
... Sonys new DFW-SX910 digital camera is ... CCD with square pixels and offers excellent ... resolution). This camera delivers uncompressed, ... easy-to-use asynchronous electronic shutter function with an ...
Medicine Products: